The core activity of Histide AG is the development and marketing of biotechnological products, in particular so-called Cell Recoding Molecules (CRM), which are intended for the treatment of rare diseases and tissue regeneration. The company focuses on the research and development of non-mutagenic extracellular therapeutic agents and has a strong patent and technology platform.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentMedical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Platform based on Cell Recoding Molecules™ and Cell Recoding Peptides™ for extracellular, non-mutagenic therapeutic approaches; designed for different cell types, indications and application formats.
Research and Development of Recoding Therapeutics™
Research, development and new applications for CRM™ in collaboration with academic partners; focus on cell biology, mechanisms of action and formulation development.
Patent and IP Management
Patent applications, drafting, prosecution, assessment, litigation and IP strategy for the CRM™ technology, as well as protection of the technology and application portfolio.
Out-licensing and Partnership Development
Partnerships and out-licensing of the technology for pharmaceutical and other application areas; business development for collaboration with strong partners.
Knowledge
No knowledge articles yet
Once HISTIDE AG has claimed this profile, we'll publish editorial articles and case studies here together.